Search This Blog

Sunday, September 26, 2021

Confusion reigns over vaccine booster rollout

 States are bracing for confusion as the Biden administration begins rolling out booster doses of Pfizer's COVID-19 vaccine.

Chaotic and at times disparate messaging from administration health officials over the past month has culminated in a complicated set of recommendations about who should be getting booster shots, and why.

A Centers for Disease Control and Prevention (CDC) advisory panel on Thursday recommended an additional dose of Pfizer's vaccine for people aged 65 and older and nursing home residents, along with people between 18 and 64 with underlying health conditions.

The panel grappled with the question of whether people in potentially high-exposure risk occupations should get a booster, but ultimately decided against recommending it.

Panel members indicated they wanted to avoid giving a recommendation that was too broad, since there was not enough evidence that vaccinated people under the age of 50 were losing protection against severe disease and hospitalization.

But in a decision announced after midnight on Friday morning, CDC Director Rochelle Walensky broke with the advisory committee and signed off on a broader policy.

Starting immediately, anyone between the ages of 18 and 64 who is at increased risk of COVID-19 "exposure and transmission because of occupational or institutional setting" can get a third dose.

Experts said Walensky's decision will make boosters available for health care workers, teachers, grocery store workers and other frontline workers. President Biden on Friday said there could be 60 million Americans who fit the bill.

But essentially, anyone who wants a third dose can get one, even though they may not technically qualify.

"There's going to be confusion. If we are going to create guidelines that are essentially making the vaccine available to almost everyone, the simplest solution is, make it available to everyone," said Celine Gounder, an infectious disease specialist and epidemiologist at NYU and Bellevue Hospital. "The best public health programs are the ones that are simple and easy to understand and clear, and the more complexity you build into it, the more difficult it is to roll out."

Gounder, who advised the Biden transition team on COVID-19, has been critical of the administration's fervent push for boosters, and said the evidence for a third dose based on occupation was mixed at best.

"You have to step back and ask the question, why is it that we're vaccinating people in high risk settings? Is it because they as individuals are at high risk, or is it because it would be disruptive to the workplace," Gounder said.

Breakthrough infections can be disruptive, especially for health workers. But if the goal of a booster shot is mainly to allay fears and anxieties among frontline workers, Gounder said, "there just isn't data to back that a young healthy health care worker is actually at risk."

Expanding the use of the Pfizer-BioNTech booster to frontline workers is still narrower than what the administration envisioned.

Last month, Biden and top health officials, including Acting Food and Drug Administration (FDA) Commissioner Janet Woodcock, Walensky and Surgeon General Vivek Murthy announced that a booster shot program for all adults would begin the week of Sept. 20, well before the FDA and CDC had examined the evidence.

The administration initially wanted people to receive boosters beginning eight months after their second shot, in an effort to reduce transmission amid the spread of the delta variant. But the scientific advisory panels decided on six months.

While officials were careful to say the booster program was contingent on the FDA and CDC giving the green light, the move was criticized by scientists inside and outside the government. They argued there wasn't enough evidence that showed protection against severe illness and hospitalization dropped to levels that warranted a booster.

During a White House briefing on Friday, Walensky acknowledged there isn’t any way for states or the federal government to ensure that people are adhering to the eligibility criteria.

"What we are doing now is self-attestation," she said.

In deciding to give boosters based on occupation, Walensky aligned CDC policy with the FDA’s authorization. But neither agency specifically defined who qualifies as a high risk worker.

Marcus Plescia, chief medical officer of the Association of State and Territorial Health Officials, said states are not expecting additional clarity from the federal government.

"That's going to be complicating, because it's not clear. I think everybody knows that health care workers are in that mix ... but there's all kinds of other occupations or institutional settings" that could meet the definition, Plescia said.

Adding further confusion, a third dose of both the Moderna and Pfizer vaccines was authorized in mid-August for people with severely weakened immune systems.

The administration's initial plan called for boosters of all three vaccines to begin at the same time, but it wasn't clear until recent weeks that only Pfizer would be able to submit clinical evidence in time.

States have been preparing for the green light from the federal government, but Plescia said it would have been easier if all three shots were authorized at the same time, or if states had flexibility to mix shots from different drug makers.

While there's no evidence about mixing a third Pfizer dose with two doses of the Moderna vaccine or a single dose of the Johnson & Johnson shot, Plescia said state health officials will have a difficult time conveying that to members of the public clamoring for boosters.

Those overpromises now create a messaging challenge, as state and federal officials need to manage expectations.

"It's much easier to make a political announcement than it is to do the hard work of analyzing science and making evidence based recommendations," said Richard Besser, a former acting CDC director.

"The fact that we won't have recommendations for people who received a Moderna and J&J because the companies haven't gotten the data in ...  that's gonna cause heartburn all over the place," said Besser, who is now president and CEO of the Robert Wood Johnson Foundation.

"People didn't have a choice of what vaccine they got. They're all effective, but only one of them can get boosted right now."

https://thehill.com/policy/healthcare/573899-confusion-reigns-over-vaccine-booster-rollout

Pfizer CEO predicts 'normal life' within a year

 Pfizer's CEO Albert Bourla said on Sunday he anticipates a return to normal life post-pandemic within the year.

"I agree that, within a year, I think will we able to come back to normal life," Bourla said on ABC's "This Week." 

Bourla added that he does not think that this means variants will no longer exist or that vaccines would be unnecessary. 

Bourla said that the "most likely scenario" was that the world would continue to see new variants and have vaccines that would last "at least a year."

"I think the most likely scenario is annual revaccination, but we don't know really. We need to wait and see the data," Bourla said.

Moderna CEO Stéphane Bancel echoed a similar sentiment to the Swiss newspaper Neue Zuercher Zeitung last week saying "enough doses should be available by the middle of next year so that everyone on this earth can be vaccinated.”

These remarks from leaders of the drug companies follow the Food and Drug Administration's (FDA) decision to move forward with recommending third-dose COVID-19 booster shots of Pfizer’s vaccine for people 65 and older as well as people with compromised immune systems.

Centers for Disease Control and Prevention Director Rochelle Walensky said last week that boosters would also be available to people in high-risk work environments such as healthcare workers.

Walensky also reiterated the notion of annual booster shots of the COVID-19 vaccine was uncertain.

https://thehill.com/homenews/sunday-talk-shows/573986-pfizer-ceo-predicts-normal-life-within-a-year

Pfizer to submit data on children's vaccines to FDA 'pretty soon'--CEO

 Pfizer CEO Albert Bourla said on Sunday that his company would begin moving forward with efforts to get children eligible for the company's COVID-19 vaccine "pretty soon."

"I think we are going to submit this data pretty soon. It's a question of days not weeks," Bourla said on ABC's "This Week." 

Bourla noted that the Food and Drug Administration (FDA) would review the data after it is submitted and make the official decisions about approval.

Bourla said Pfizer would be ready to manufacture more doses for children if needed. He added that children ages 5 to 11 would receive about one-third of the dose adults receive. 

Pfizer announced on Sept. 20 that research showed its vaccine was safe and effective for children ages 5 to 11.

"Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine," Bourla said at the time of that announcement. "We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children." 

https://thehill.com/homenews/sunday-talk-shows/573987-pfizer-to-submit-data-on-childrens-vaccines-to-fda-pretty-soon-ceo

CDC Not Changing Definition Of 'Fully Vaccinated'...For Now: Walensky

 by Jack Phillips via The Epoch Times,

Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said Friday that the definition of “fully vaccinated” won’t change when COVID-19 booster shots are rolled out—at least in the near future.

Currently, the CDC and other federal health agencies have defined one as fully vaccinated if they receive two doses of the Pfizer-BioNTech vaccine, two doses of Moderna’s vaccine, or one Johnson & Johnson shot.

In Israel, officials recently announced individuals who have not received a third dose of the Pfizer vaccine after six months will not be counted as fully vaccinated.

It means they won’t be able to use the “green pass” vaccine passport that is utilized for restaurants, gyms, and other venues in Israel.

When asked whether the CDC will change its definition, Walensky said that “we are not changing the definition right now of fully vaccinated.”

As the agency gathers more “experience with our third shot and have more people who are recommended” to get the shot, then the CDC may change its guidelines around boosters, Walensky said during the White House’s COVID-19 response team briefing.

Across the United States, some businesses and government agencies have made it mandatory for workers to get fully vaccinated against COVID-19. Should the CDC and other health agencies change its policy around who can be considered fully vaccinated, the rule would potentially impact tens of millions of people.

Several weeks ago, Israel, which has one of the most vaccinated populations in the world, set an expiration date for its vaccine passport. Now, a booster shot received within six months of the second dose extends the passport’s validity by six months.

That decision came just days after the country started offering COVID-19 boosters to all vaccinated people.

Walenksy’s remarks come just hours after a CDC panel on late Thursday recommended Pfizer boosters for individuals aged 65 and older. The panel also overwhelmingly voted for a booster for people between the ages of 50 and 64 who have underlying health issues, and voted in favor of providing the third dose for anyone who is being treated at a long-term care facility.

“Prevention of infection may protect health care capacity and other essential services for the COVID-19 response and maintain overall function for society,” said Dr. Kathleen Dooling, a CDC official on the panel.

The World Health Organization has sharply criticized the U.S., Israel, and other wealthy nations for trying to develop and approve booster doses for their populations, arguing that poorer countries are still in dire need of COVID-19 vaccines.

https://www.zerohedge.com/covid-19/cdc-not-changing-definition-fully-vaccinatedfor-now-walensky

Saturday, September 25, 2021

Orthopedic medical device company Paragon 28 files for a $100 million IPO

 Paragon 28, which makes orthopedic implants and medical devices for the foot and ankle, filed on Friday with the SEC to raise up to $100 million in an initial public offering.


Paragon 28 states that it is a leading medical device company exclusively focused on the foot and ankle orthopedic market. Its orthopedic solutions, procedural approaches, and instrumentation cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD, or flatfoot), charcot foot, and orthobiologics. The company provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation, and its suite of surgical solutions comprises 72 product systems and approximately 8,700 SKUs.

The Englewood, CO-based company was founded in 2010 and booked $134 million in sales for the 12 months ended June 30, 2021. It plans to list on the NYSE under the symbol FNA. Paragon 28 filed confidentially on August 2, 2021. BofA Securities, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.

Federal appeals court blocks NYC teacher vaccine mandate

 A federal appeals court blocked New York City’s coronavirus vaccine mandate late Friday evening, dealing a blow to the city days before the mandate goes into effect. 

The 2nd Circuit Court of Appeals granted an expedited injunction on Friday blocking the city from mandating that all public school employees submit proof of their first coronavirus vaccine dose by Monday.

The court referred the case to a three-judge panel on an expedited basis.

New York City Mayor Bill de Blasio (D) said in late August that all of the city’s public school teachers and staff would need to have their first dose by Sept. 27. There was no alternative option for regular testing.

A group of New York City public school employees sued earlier this month to block the mandate, arguing that their rights to due process and equal protection were violated. The complaint specifically alleged that the order violated their right to pursue their profession. 

On Thursday, U.S. District Judge Brian Cogan upheld the mandate, prompting the plaintiffs to quickly appeal the decision. 

About 82 percent of the city’s roughly 149,000 public school employees are vaccinated, the agency told The Hill, including 88 percent of roughly 78,000 teachers and 95 percent of roughly 1,600 principals.

Danielle Filson, press secretary for the New York City Department of Education [DOE], said in a statement to The Hill that the agency is “confident our vaccine mandate will continue to be upheld once all the facts have been presented, because that is the level of protection our students and staff deserve.”

“Over 82 percent of DOE employees have been vaccinated and we continue to urge all employees to get their shot by September 27,” Filson said.

https://thehill.com/policy/healthcare/573942-federal-appeals-court-blocks-nyc-teacher-vaccine-mandate

COVID-19 vaccine boosters could mean billions for drugmakers

 Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans' protection against the virus.

How much the manufacturers stand to gain depends on how big the rollout proves to be.

U.S. health officials late on Thursday endorsed booster shots of the Pfizer  for all Americans 65 and older—along with tens of millions of younger people who are at higher risk from the coronavirus because of health conditions or their jobs.

Officials described the move as a first step. Boosters will likely be offered even more broadly in the coming weeks or months, including boosters of vaccines made by Moderna and Johnson & Johnson. That, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.

"The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost," Jefferies analyst Michael Yee said.

Wall Street is taking notice. The average forecast among analysts for Moderna's 2022 revenue has jumped 35% since President Joe Biden laid out his  plan in mid-August.

Most of the vaccinations so far in the U.S. have come from Pfizer, which developed its shot with Germany's BioNTech, and Moderna. They have inoculated about 99 million and 68 million people, respectively. Johnson & Johnson is third with about 14 million people.

No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in  next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans.

Those companies also may gain business from people who got other vaccines initially. In Britain, which plans to offer boosters to everyone over 50 and other vulnerable people, an expert panel has recommended that Pfizer's shot be the primary choice, with Moderna as the alternative.

Andersen expects Moderna, which has no other products on the market, to generate a roughly $13 billion profit next year from all COVID-19 vaccine sales if boosters are broadly authorized.

Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the "high 20s" as a percentage of revenue. That would translate to a profit of around $7 billion next year just from boosters, based on Andersen's sales prediction.

J&J and Europe's AstraZeneca have said they don't intend to profit from their COVID-19 vaccines during the pandemic.

For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won't come with the research and development costs the companies incurred to get the vaccines on the market in the first place.

WBB Securities CEO Steve Brozak said the booster shots will represent "almost pure profit" compared with the initial doses.

Drugmakers aren't the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a  with Gabelli Funds.

Jonas noted that the drugstores may not face competition from mass vaccination clinics this time around, and the chains are diligent about collecting customer contact information. That makes it easy to invite people back for boosters.

Drugmakers are also developing COVID-19 shots that target certain variants of the virus, and say people might need annual shots like the ones they receive for the flu. All of that could make the vaccines a major recurring source of revenue.

The COVID-19 vaccines have already done much better than their predecessors.

Pfizer said in July it expects revenue from its COVID-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of boosters or the possible expansion of shots to .

That would be more than five times the $5.8 billion racked up last year by the world's most lucrative vaccine—Pfizer's Prevnar13, which protects against pneumococcal disease.

It also would dwarf the $19.8 billion brought in last year by AbbVie's rheumatoid arthritis treatment Humira, widely regarded as the world's top-selling drug.

This bodes well for future vaccine development, noted Erik Gordon, a business professor at the University of Michigan.

Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the COVID-19 shots could draw more drugmakers and venture capitalists into the field.

"The vaccine business is more attractive, which, for those of us who are going to need vaccines, is good," Gordon said.

https://medicalxpress.com/news/2021-09-covid-vaccine-boosters-billions-drugmakers.html